Clinical trials: Dementia Disorders
Alzheimer's Disease
ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease
The purpose of this study is to evaluate the long-term safety and tolerability of ELND005 beyond the 18 months of treatment in original randomized and blinded clinical trail ELND005-AD201.
- Trial name
- NCT00934050
- Testing
- ELND005 (scyllo-inositol)
- Where
- 38 sites in United States, Canada
- Volunteers
- 103 people
- Sponsor
- OPKO Health, Inc.
Alzheimer Disease
Open-Label Extension Protocol to SNK01-AD01 Study
Open-Label Extension Protocol to SNK01-AD01 Study
- Trial name
- NCT07228078
- Testing
- SNK01
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- NKGen Biotech, Inc.
Dementia, Alzheimer's Disease
Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia
The purpose of this trial is to test the safety \& tolerability of intramuscular aripiprazole in acutely agitated patients diagnosed with Dementia.
- Trial name
- NCT00095719
- Testing
- Aripiprazole
- Where
- 14 sites in United States
- Volunteers
- 125 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Early Alzheimer's Disease
A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects
The primary objective of the study is to evaluate the effects of hepatic impairment on the pharmacokinetics (PK) of E2609 after a single dose administration.
- Trial name
- NCT02859207
- Testing
- E2609
- Where
- 3 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Alzheimer Disease, Alzheimer Disease, Late Onset
Safety and Efficacy of Transcranial Electromagnetic Treatment Against Alzheimer's Disease
The purpose of this study is to determine the safety and initial efficacy of Transcranial Electromagnetic Treatment (TEMT) in patients with mild/moderate Alzheimer's Disease.
- Trial name
- NCT02958930
- Testing
- MemorEM 1000
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- NeuroEM Therapeutics, Inc.
Agitation, Alzheimer's Type Dementia
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
This study will be conducted to evaluate the efficacy, safety, tolerability, and pharmacokinetics of masupirdine compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer's type.
- Trial name
- NCT05397639
- Testing
- Masupirdine 50 mg, Masupirdine 100 mg
- Where
- 44 sites in United States, Croatia and 2 more
- Volunteers
- 375 people
- Sponsor
- Suven Life Sciences Limited
Alzheimer's Disease, Dementia
Study of the Safety and Clinical Effects of 2 Doses of EVP-6124 in Subjects With Alzheimer's Disease Who Complete Study EVP-6124-024 or EVP-6124-025
This is a 26-week, randomized extension of the Phase 3 double-blind placebo-controlled studies, EVP-6124-024 and EVP-6124-025. In this extension study, subjects who complete study EVP-6124-024 or EVP-6124-025 and fulfill all…
- Trial name
- NCT02004392
- Testing
- EVP-6124
- Where
- 86 sites in United States, Australia and 10 more
- Volunteers
- 348 people
- Sponsor
- FORUM Pharmaceuticals Inc
Alzheimer's Disease
A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205
The primary objective is to evaluate the safety and tolerability of aducanumab over 100 weeks of treatment after a wash-out period imposed by discontinuation of feeder studies in participants who had previously received…
- Trial name
- NCT04241068
- Testing
- Aducanumab
- Where
- 297 sites in United States, Australia and 18 more
- Volunteers
- 1,696 people
- Sponsor
- Biogen
Alzheimer's Disease
Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil
This study will evaluate safety and efficacy of PF-05212377 in subjects with mild-to-moderate Alzheimer's Disease with existing neuropsychiatric symptoms on a stable dose of Donepezil.
- Trial name
- NCT01712074
- Testing
- PF-05212377 (SAM-760)
- Where
- 60 sites in United States, Canada and 5 more
- Volunteers
- 186 people
- Sponsor
- Pfizer
Alzheimer Disease, Alzheimer's Disease (Incl Subtypes)
Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - PAST Extension
The primary objective of the study is to evaluate whether a set of algorithms analysing acoustic and linguistic patterns of speech can detect amyloid-specific cognitive impairment in early stage Alzheimer's disease, based on…
- Conditions
- Alzheimer Disease, Alzheimer's Disease (Incl Subtypes), Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease
- Trial name
- PAST-US (NCT04937959)
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Novoic Limited
Alzheimer Disease
A Study of the Safety and Effectiveness of Galantamine Hydrobromide in Patients With Alzheimer's Disease
The purpose of this study is to evaluate the safety and effectiveness of galantamine hydrobromide in patients with Alzheimer's disease who have not received or have not responded to treatment with medication similar to…
- Trial name
- NCT00297362
- Testing
- Galantamine hydrobromide
- Volunteers
- 344 people
- Sponsor
- Janssen Cilag Pharmaceutica S.A.C.I., Greece
Dementia, Dementia, Vascular
The BRAIN App: Building Relationships Using Artificial Intelligence and Nostalgia
This study will involve testing of an Alpha version of an app called "Building Relationships using Artificial Intelligence and Nostalgia" or BRAIN.
- Conditions
- Dementia, Dementia, Vascular, Alzheimer Disease, Dementia, Mixed
- Trial name
- BRAIN (NCT05515679)
- Testing
- The BRAIN App
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Hopeful Aging
Agitation
Phase IV to Evaluate the Safety of Self-administered ADASUVE® in Agitated Patients Outside the Hospital Setting
Phase IV, multinational, multicentre, open-label, non-randomized, clinical trial conducted in Europe (Spain, Germany, Finland, Norway, Romania and Austria) to evaluate the safety profile of ADASUVE® in agitated patients with…
- Trial name
- NCT02525991
- Testing
- Staccato® Delivery System Loxapine (ADASUVE®)
- Where
- Spain
- Volunteers
- 323 people
- Sponsor
- Ferrer Internacional S.A.
Alzheimer's Disease
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
This is a multi-center, randomized, double-blind placebo-controlled safety study conducted in 2 study cohorts. In Cohort 1, subjects with Alzheimer's disease (n=250) will receive Dimebon 20 mg or placebo TID for 26 weeks.
- Trial name
- NCT00838110
- Testing
- Dimebon
- Where
- 118 sites in United States, Canada and 1 more
- Volunteers
- 742 people
- Sponsor
- Pfizer
Dementia
A Study on Behavioral and Psychological Symptoms of Dementia
The purpose of this observational study is to obtain the current status of patients with Behavioral and Psychological Symptoms of Dementia.
- Trial name
- NCT00641459
- Testing
- Observational BPSD treatment study
- Volunteers
- 359 people
- Sponsor
- Johnson & Johnson Taiwan Ltd
Alzheimer Disease
Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult Male Subjects
Open-label, single-dose study to assess the absorption, metabolism, excretion and mass balance of [C14] CT1812
- Trial name
- COG0108 (NCT05225389)
- Testing
- 300 mg [C14] CT1812
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Cognition Therapeutics
Early Alzheimer's Disease
An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
This study is being conducted to evaluate the safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 genotype.
- Trial name
- APOLLOE4 (NCT04770220)
- Testing
- Experimental: ALZ-801
- Where
- 95 sites in United States, Canada and 7 more
- Volunteers
- 325 people
- Sponsor
- Alzheon Inc.
Frontotemporal Lobar Degeneration (FTLD), Frontotemporal Dementia (FTD)
Digital Measurements of Motor and Voice Functions in FTD
The primary objective of this clinical study is to provide the initial validation for monitoring biomarkers of symptoms and functioning for individuals with FTLD syndromes.
- Conditions
- Frontotemporal Lobar Degeneration (FTLD), Frontotemporal Dementia (FTD), Corticobasal Syndrome, Corticobasal Syndrome(CBS)
- Trial name
- NCT07333898
- Volunteers
- 20 people
- Sponsor
- BioSensics
Alzheimer Disease, Alzheimer Disease Due to P. Gingivalis
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
This study is to test LHP588 in persons who have mild to moderate Alzheimer's disease (AD) who have shown progressive mental decline in the last year and who have P. gingivalis (Pg) infection. P.
- Trial name
- NCT06847321
- Testing
- LHP588
- Where
- 39 sites in United States
- Volunteers
- 300 people
- Sponsor
- Lighthouse Pharmaceuticals, Inc.
Alzheimer Disease
A Study of the Effects on Sleep, Attention, and Gastrointestinal Tolerance of Galantamine and Donepezil in Patients With Alzheimer's Disease
The purpose of this study is to evaluate the relative effects of galantamine compared to donepezil (both cholinesteraste inhibitors), on sleep, attention, and gastrointestinal tolerance in patients with Alzheimer's disease.
- Trial name
- NCT00035204
- Testing
- galantamine
- Volunteers
- 63 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.